The Twenty-Minute Question: What CRISPR Diagnostics Must Prove Before They Reach a GP's Desk

A ten-minute GP appointment is a poor place for a laboratory result to arrive late. Yet that is the promise, and the problem, of CRISPR diagnostics. Cas-based tests can identify a pathogen or a resistance gene with a specificity that once required a central lab. In the right setting, they can return an answer in under an hour. The question for the NHS in late 2026 is whether the right setting is a general practice.

The appeal is easy to state. A patient presents with fever and a cough; a swab is taken; a disposable cartridge reports influenza, RSV or SARS-CoV-2 before the consultation ends. A clinician can then prescribe, isolate or reassure with more confidence. That is a compelling pathway. But the NHS does not adopt technologies because they are elegant. It adopts them when they change a decision, fit a workflow and survive an economic test. For CRISPR diagnostics, the surgery is the hardest exam.

A different kind of laboratory

CRISPR diagnostics do not edit human DNA. They use Cas proteins as molecular detectors, pairing a guide RNA with a target sequence and converting recognition into a signal. The science is ingenious. Primary care, however, is not a laboratory with a waiting room attached. It is a high-volume, low-margin service in which a healthcare assistant may take the sample, a practice nurse may run the test and a GP may have eight minutes to act on it.

That changes the specification. A central laboratory can batch samples, run controls and employ biomedical scientists. A surgery needs a cartridge that is stable at room temperature, a reader that is easy to clean and a result that is unambiguous. It also needs connectivity. A standalone reader that cannot talk to EMIS or SystmOne creates a second silo, and a second silo is a patient safety risk.

The stewardship argument

The strongest case for near-patient CRISPR testing is antimicrobial stewardship. Most sore throats are viral. FeverPAIN and CRP already help clinicians decide when antibiotics are unlikely to help. A rapid test that distinguishes bacterial from viral infection, or identifies a resistance marker, could sharpen that decision. In principle, it could reduce unnecessary prescribing without denying treatment to those who need it.

In practice, the evidence bar is higher than analytical sensitivity. A test validated in hospital patients with a high pre-test probability may perform poorly in general practice, where prevalence is lower and the consequences of a false negative are different. NICE's diagnostics assessment route will want to see clinical utility, not just accuracy. Does the test change prescribing? Does it reduce reconsultations? Does it improve outcomes or merely document them? A result that arrives after the patient has already been given amoxicillin has not delivered stewardship.

Winter, panels and the NHS bottleneck

Respiratory infection is the obvious beachhead. Winter pressures expose the limits of central laboratory turnaround, and multiplex panels can rule out several viruses at once. For care homes and urgent treatment centres, a same-day result could support cohorting and reduce unnecessary admissions. For general practice, the benefit is less certain. A single-pathogen test may be less useful than a panel, and a panel may be too expensive for routine use.

The NHS also has a habit of buying devices and then discovering the pathway. A CRISPR kit is not a service. It needs sample collection, transport, quality control, training, waste disposal and a result that lands in the right part of the record. The UK Health Security Agency's surveillance systems and local infection teams will want data too. A diagnostic that improves individual care but weakens public health reporting is not a neutral innovation.

Regulation is the entry ticket

Before any of this reaches a consulting room, the manufacturer must satisfy the MHRA's requirements for in vitro diagnostics, including UKCA marking where applicable. That means analytical and clinical performance data, a quality management system and post-market surveillance. It is a necessary hurdle, not a sufficient one.

Commissioning is the next gate. The NHS does not purchase tests in the abstract; it purchases pathways. An integrated care board will ask whether a new test is affordable within the tariff, whether it displaces an existing test and whether the workforce can deliver it. NICE guidance may support adoption, but local decisions still depend on budgets and capacity. A cheap test can be expensive if it triggers unnecessary follow-up, and an expensive test can be cost-effective if it prevents admissions.

What a credible UK trial would look like

The UK has an advantage: a single health system with linked data and a strong primary care research network. A credible trial would be pragmatic and cluster randomised, recruiting practices in deprived urban areas and rural communities rather than only in well-resourced teaching sites. It would measure antibiotic prescribing, reconsultation, hospital admission, cost per quality-adjusted life year and, where possible, resistance outcomes.

It would also test the unglamorous parts: sample handling by non-laboratory staff, result interpretation under time pressure, and equity of access. A test that works only in practices with a research nurse and a stable internet connection is not a general practice test. It is a pilot.

Where it might land first

The first NHS foothold is unlikely to be every surgery. It is more likely to be a defined pathway: a primary care network hub with a reader, a same-day urgent care service, a care home outbreak, or a sexual health clinic where a rapid result changes immediate treatment. Hub-and-spoke models could manage quality control and keep costs down. That would be a sensible start, but it would not settle the twenty-minute question.

That question remains the right one. A CRISPR diagnostic earns a place in general practice only when it delivers an actionable result within the consultation, fits the record, survives the evidence test and proves affordable across the NHS. Until then, the consulting room should be interested but sceptical. The technology can detect. The health service must still decide.